Prenetics Adds Longevity CEO Dr. Darshan Shah to Board, Bolstering IM8 Growth Strategy
Event summary
- Prenetics appointed Dr. Darshan Shah, a longevity expert and CEO of Next Health, to its Board of Directors on February 16, 2026.
- Dr. Shah brings over 20 years of clinical experience, including 20,000+ surgeries, and entrepreneurial expertise in health optimization.
- He will serve on the Audit, Compensation, and Nominating Committees, aligning with Prenetics' IM8 growth strategy.
- Dr. Shah recently gained national recognition for his role in Liquid Death's Super Bowl LX advertisement.
- Prenetics' IM8 brand has surpassed $100 million in annualized recurring revenue within 11 months of operations.
The big picture
Prenetics' appointment of Dr. Darshan Shah underscores its commitment to merging clinical rigor with consumer appeal in the burgeoning longevity sector. With IM8's rapid revenue growth and high-profile partnerships, the move signals a strategic push to solidify its position as a leader in science-backed health optimization. The addition of Shah's entrepreneurial and medical expertise could accelerate Prenetics' ability to scale IM8 globally, though execution risks remain.
What we're watching
- Strategic Fit
- How Dr. Shah's dual expertise in clinical science and mass-market product formulation will drive IM8's global expansion.
- Execution Risk
- Whether Prenetics can sustain IM8's rapid revenue growth while scaling its clinical trials and data-driven product development.
- Market Positioning
- The pace at which Prenetics can differentiate IM8 in the competitive premium health and longevity market.
Related topics